Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2007

Vegenics Licenses Antibodies from CoGenesys

  • Vegenics licensed from CoGenesys exclusive, worldwide rights to human mAbs that target vascular endothelial growth factor-C (VEGF-C). VEGF-C is believed to play an important role in promoting the formation of new blood vessels and the maintenance of existing blood vessels.

    "Our partnership with Vegenics is a great example of our business model, in which multiple, early-stage partnering agreements will generate a continuing revenue stream to support our own internal development activities," says Mark Rampy, CBO of CoGenesys.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »